STOCK TITAN

Qiagen N.V. - $QGEN STOCK NEWS

Welcome to our dedicated page for Qiagen N.V. news (Ticker: $QGEN), a resource for investors and traders seeking the latest updates and insights on Qiagen N.V. stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Qiagen N.V.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Qiagen N.V.'s position in the market.

Rhea-AI Summary

QIAGEN has received European IVDR certification for its QIAGEN Clinical Insight Interpret, a clinical decision support software for next-generation sequencing (NGS) in oncology and hereditary applications. This certification ensures the platform complies with the EU's regulatory framework, enhancing patient safety, data transparency, and traceability. The software has already processed over 4 million NGS patient test cases globally. The certified version will be available in Europe by late 2024, facilitating faster and more accurate clinical decision-making.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
none
-
Rhea-AI Summary

QIAGEN has received FDA clearance for its QIAstat-Dx Respiratory Panel Plus, a syndromic test for diagnosing upper respiratory infections. The panel covers 21 viral and bacterial targets, delivers results in about an hour with minimal hands-on time, and provides access to Ct values and amplification curves. This technology aims to improve patient care, support antimicrobial stewardship, and reduce healthcare system burden. QIAGEN is expanding its testing menu, with a Gastrointestinal Panel under FDA review. The company also launched the QIAstat-Dx Analyzer 2.0, featuring cloud-based connectivity and remote result access, enhancing collaboration in healthcare.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
-
Rhea-AI Summary

QIAGEN partners with the FBI to develop a novel digital PCR assay for QIAcuity to enhance DNA analysis in forensics, improving accuracy, speed, and reliability in human identification. The collaboration aims to quantify DNA from human samples for forensic use, strengthening QIAGEN's leadership in human identification and forensics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.02%
Tags
partnership
Rhea-AI Summary

QIAGEN has launched QCI Secondary Analysis, a cloud-based software solution that enhances bioinformatics workflows for oncology and inherited disease applications. The software, integrated with QCI Interpret, enables high-throughput secondary analysis of clinical next-generation sequencing data, advancing precision medicine and making NGS testing accessible to smaller labs. The solution provides a secure and compliant environment for bioinformatics workflows, supporting all QIAGEN QIAseq panels.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
none
-
Rhea-AI Summary

QIAGEN reported its Q1 2024 results, showcasing net sales of $459 million with a 5% decline, but exceeded expectations with $462 million at constant exchange rates. The company's adjusted operating income margin rose to 25.7% from 25.6% in Q1 2023, with adjusted diluted EPS at $0.46, above the outlook of $0.44. Key growth drivers include double-digit CER growth in QuantiFERON and QIAstat-Dx, resulting in a positive outlook for 2024 with reaffirmed guidance of at least $2.0 billion in net sales and adjusted diluted EPS of at least $2.10 CER.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
-
Rhea-AI Summary
QIAGEN launches the QIAseq xHYB Mycobacterium tuberculosis Panel for research use to support real-time TB surveillance and combat antimicrobial resistance. The panel enables culture-free whole genome sequencing, accelerates TB outbreak tracking, and aids in detecting drug-resistant strains. The innovation addresses critical needs in TB management amid rising incidence rates globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
none
Rhea-AI Summary
QIAGEN N.V. (QGEN) announced plans to release results for the first quarter 2024. The press release date is set for Monday, April 29, shortly after 22:05 Frankfurt time, with a conference call scheduled for Tuesday, April 30. Investors can join the call via phone or webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
-
Rhea-AI Summary
QIAGEN N.V. introduces new products to boost cancer research and liquid biopsy capabilities, including dPCR PanCancer Kits for detecting EGFR and BRAF mutations, a Targeted RNA-seq Panel for T-cell receptors, and a Urine Liquid Biopsy Set for non-invasive sample collection and DNA stabilization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.91%
Tags
none
-
Rhea-AI Summary
QIAGEN releases QIAstat-Dx Analyzer 2.0 with Software 1.6, offering mobile access to test results, improved epidemiology dashboards, and enhanced remote system management. Over 4,000 QIAstat-Dx instruments placed globally by 2023 for reliable diagnosis of complex syndromes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
none
Rhea-AI Summary
QIAGEN partners with IPPA to educate on IGRA benefits for healthcare providers and support new TB screening requirements. Updated U.S. CDC guidelines mandate IGRA testing for immigrants aged 2 and older. QIAGEN to host global event before World TB Day on March 21.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
partnership
Qiagen N.V.

NYSE:QGEN

QGEN Rankings

QGEN Stock Data

9.54B
219.34M
0.42%
74.25%
1.61%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
Venlo

About QGEN

qiagen is the leading global provider of sample to insight solutions to transform biological materials into valuable molecular insights. qiagen sample technologies isolate and process dna, rna and proteins from blood, tissue and other materials. assay technologies make these biomolecules visible and ready for analysis. bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. automation solutions tie these together in seamless and cost-effective molecular testing workflows. qiagen provides these workflows to more than 500,000 customers around the world in molecular diagnostics (human healthcare), applied testing (forensics, veterinary testing and food safety), pharma (pharmaceutical and biotechnology companies) and academia (life sciences research). as of june 30, 2015, qiagen employed approximately 4,400 people in over 35 locations worldwide. further information can be found at http://www.qiagen.com.